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Abstract 
Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. 
Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who 
have co-morbidities and are on chronic medications. 
Study design. All HCV-infected patients over 65 years old in clinical follow-up at two Hospitals in Spain who 
initiated anti-HCV therapy were included (August 2012–October 2015). 
Results. A total of 120 HCV mono-infected patients were recorded. Mean age of patients was 
72.6 ± 7.4 years. There were 53.3% women and GT1b was the most frequent (83.3%); 64.2% had cirrhosis 
and 42.5% were treatment experienced. Ombitasvir + Paritaprevir/r ± Dasabuvir ± Ribavirin (RBV) and 
sofosbuvir/ledipasvir ± RBV were the most frequently used regimens. Weight-adjusted dosing of RBV was 
included in 61.7% and 43.6% of them required a dose reduction. Most of the patients (86.7%) had 
concomitant chronic medication and in 35.8% adjustment was necessary. Adverse events (AE) were seen in 
65% of the patients; more frequent when a protease inhibitor (PI) was being used. The sustained virological 
response (SVR12) per ITT was 88.3%. Only 3 patients discontinued treatment and 2 patients died. 
Conclusions. High rates of SVR12 (88.3%) were observed among elderly patients with DAAs-based 
regimens. The presence of AE was frequent (65%). The majority of these patients (86.7%) had concomitant 
medication that required adjustment in 1/3 of them. These findings highlight the high rates of response to 
DAAs in the elderly HCV-population. However, special caution must be taken when using RBV and a PI. 
  
Graphical abstract 
 
 
High rates of SVR12 (88.3%) were observed among elderly patients with DAAs-
based regimens. The majority of these patients (86.7%) had concomitant 
medication that required adjustment in 1/3 of them. The presence of adverse event 
was frequent (65%) during HCV treatment, more frequent when a protein inhibitor 
or ribavirin was part of the regimen. Adverse events and modification of chronic 
medications make these patients a special population, where we had to exercise 
more care. 
1. Backgorund 
Hepatitis C Virus infection (HCV) continues to be a major public health problem affecting 
130–150 million people globally [1]. The prevalence of chronic hepatitis C virus (CHC) infection 
in Spain is estimated around 2.5%–2.9%, and it increases with age [2]; [3]; [4]; [5]. Most studies 
have consistently found that age and age onset of infection are major factors influencing the degree 
of fibrosis. In patients over 50-years-old, the rate of progression of fibrosis accelerates, regardless 
of the duration of infection [6]; [7]. 
 
Moreover, age has been a major limitation using pegylated interferon (Peg-IFN) and RBV 
because its poor tolerability and poorer response in older patients [8]; [9]; [10]. The new DAAs 
have demonstrated high efficacy, safety and tolerability. Therefore, elderly patients in whom co-
morbidities and concomitant chronic medications exist, might benefit from these therapies. 
However, these patients represented less than 15% in clinical trials and were mainly non-cirrhotic, 
in contrast with the real life population [11]. 
  
2. Objectives 
In this context, the purpose of this study is to analyse the efficacy and safety of different anti 
HCV treatments including DAAs in a real-life cohort of elderly patients. 
3. Study design 
This is an observational prospective study including all CHC infected patients over 65 years 
old who received HCV treatment based on DAAs at two hospitals in the Northwest Spain between 
August 2012 and October 2015. 
 
The study protocol was reviewed and approved by a Medical Ethics Committee and this 
publication is in accordance with the community standards. All the study participants were 
informed before the study inclusion. 
 
All demographic, virological, clinical, laboratory, liver fibrosis status, antiviral regimen, the 
pharmacotherapeutic profile and adherence data were recorded. 
 
The treatment options available for HCV therapies based on DAAs during the study period 
were: telaprevir(TEL)/boceprevir(BOC)/simeprevir(SIM)/sofosbuvir(SOF) + Peg-IFN + RBV, 
SOF + RBV, SOF + ledipasvir(LDV) ± RBV, ombitasvir + paritaprevir/ritonavir (2D) ± dasabuvir 
(3D) ± RBV, SOF + SIM ± RBV and SOF + daclatasvir(DCV) ± RBV. Co-morbidities, chronic 
medications, HCV status and facilities to an appropriate adherence were taken into consideration 
for best treatment selection. 
 
The virological endpoint was the achievement of SVR12. Adverse events (AE), changes in 
chronic medication and adherence were recorded as secondary clinical endpoints. 
 
A descriptive analysis was performed for all variables. Continuous variables were reported 
using means ± standard deviations or median (range), as indicated. For dichotomous/categorical 
variables, absolute numbers and percentages were computed. The comparison of quantitative 
parameters was carried out using Student’s t/Mann-Whitney test, as appropriate. The association 
of qualitative variables was carried out using Chi-squared statistic. An intention to treat analysis 
(ITT) was done, to evaluate SVR12. Statistical analysis was performed using SPSS for Windows 
(version 19.0, SPSS Inc., Chicago, Illinois). 
4. Results 
A total of 120 CHC monoinfected patients were included. Main demographic and virological 
characteristics are described in Table 1. Mean age of patients was 72.6 ± 7.4 years, there were 
53.3% women, 100% were caucasian and GT1b was the most frequent (83.3%). 64.2% had 
cirrhosis. 
  
Table 1. Demographic and virological characteristics of the study population. 
 n=120 
  
Gender, % (n) 
 
 Men 46.7 (56) 
 Women 53.3 (64) 
Age, years old; mean ± SD 72.6 ± 7.4 
>80 years old, % (n) 10.8 (13) 
Genotype, %(n) 
 
 1a 5.8 (7) 
 1b 83.3 (100) 
 1, unknown subtype 6.7 (8) 
 2 2.5 (3) 
 3 0.8 (1) 
 4 0.8 (1) 
HCV RNA viral load, log UI/mL; median (range) 6.08 (4.09−7.9) 
Fibrosis stage, % (n) 
 
 F0-F1 4.2 (5) 
 F2 10.8 (13) 
 F3 20.8 (25) 
 F4 64.2 (77) 
Child Pugh Score, % (n) 
 
 A 95.0 (71) 
 B 5.0 (6) 
Fibrosis measured by Fibroscan, kPa; median (range) 17.4 (1.1–48.0) 
Previous exposure to treatment, % (n) 
 
 Naive 57.5 (69) 
 Relapser 11.7 (14) 
 Partial responder 6.7 (8) 
 Null responder 16.7 (20) 
 Unknown response 7.5 (9) 
  
 
The specific treatment combinations and the AE related to the study medication are depicted in 
Table 2. Briefly, 3D/2D ± RBV and SOF/LDV ± RBV were the most frequently used regimens. 
The duration of HCV treatment was in the majority of the cases (82.6%) 12 weeks. 
  
Table 2. HCV regimens used in the study population. 
HCV regimens used in the study population n = 120 (%) 
  
Ombitasvir + Paritaprevir/r + Dasabuvir + Ribavirin 31 (25.8%) 
Ombitasvir + Paritaprevir/r + Dasabuvir 23 (19.2%) 
Sofosbuvir + Ledipasvir 19 (15.8%) 
Sofosbuvir + Ledipasvir + Ribavirin 13 (10.8%) 
Sofosbuvir + Simeprevir + Ribavirin 11 (9.2%) 
Telaprevir + Interferon + Ribavirin 7 (5.8%) 
Sofosbuvir + Simeprevir 5 (4.2%) 
Simeprevir + Interferon + Ribavirin 3 (2.5%) 
Sofosbuvir + Ribavirin 3 (2.5%) 
Sofosbuvir + Daclatasvir + Ribavirin 2 (1.7%) 
Boceprevir + Interferon + Ribavirin 2 (1.7%) 
Ombitasvir + Paritaprevir/r + Ribavirin 1 (0.8%) 
Adverse events in the study population n = 120 (%) 
Adverse events 78 (65.0%) 
Asthenia 47 (39.2%) 
Anemia 45 (37.5%) 
Pruritus and dried mucosas 20 (16.5%) 
Hyperbilirubinemia 14 (11.7%) 
Insomnia 4 (3.3%) 
Irritability 3 (2.5%) 
Liver decompensation 1 (0.8%) 
Ascites  
Encephalopaty  
  
 
Most patients (69.2%) received a PI based regimen. Many of them had at least one AE 
compared to those who were not exposed to a PI (74.7% vs. 45.9%; OR: 3.49, CI95%: 1.54–7.84, 
p = 0.002). This association remained significant even after adjustment for the use of RBV: the OR 
for PI use was 3.10 (CI95%: 1.20–8.00, p = 0.019) and for RBV use was 10.17 (CI95%: 4.10–
25.23, p < 0.001). 
 
Weight-adjusted dosing of RBV was included in 61.7% of regimens and 43.6% of them 
required a dose reduction. This dose reduction was mostly related to anemia and was performed on 
week 4 of treatment in the majority of the patients (61.8%). 
 
Two hepatocellular carcinomas (HCC) were diagnosed after the initiation of DAA regimen in 
two cirrhotic patients, they were following HCC screening program before the initiation of the 
study medication; one of them with an ultrasound image at the beginning of HCV treatment, with 
no evidence of tumour. 
 
Most patients (86.7%) had concomitant chronic medication; 77.6% had at least one additional 
chronic medication. The most frequent chronic medications were antihypertensive (58.3%), proton 
pump inhibitors (27.5%), benzodiazepines (22.5%), antidiabetic agents (17.5%) and statin (10%). 
Before the initiation of HCV treatment, an adjustment of medication was needed for 35.8% of 
patients, mainly for antihypertensive and statins therapies. During the study period, 3 patients 
discontinued therapy (2.5%).  
The ITT analyses showed a SVR12 of 88.3%, while 95.5% per protocol of the study 
population achieved SVR12. Five relapsers were seen: three of them were treated with an IFN-
based regimen, all of them before SVR12. There are 9 patients with missing data of SVR12: 3 
cases were related to the diagnosis of another illness (2 HCC and 1 cholangiocarcinoma); 1 case 
because the patient is in the follow-up (FU) period, as the study period concluded before SVRS12; 
for 3 cases because there were lost to FU of these patients and 2 patients died. No associated factor 
was linked to treatment failure. 
 
The study population had an adherence to therapy over 80% in 97.3% of cases. Adherence was 
carefully recorded by validated tests, an indirect method of recount of the study medication: 
Adherence% = [(Dispensed medication – Returned medication)/Prescription medication] × 100. 
 
Two patients died during the study period. One patient died two months after end of treatment 
related to subdural hematoma. The other patient was a 69-year-old female with compensated 
cirrhosis, who died of unknown causes during treatment with SOF + LDV on week 20. 
5. Discussion 
This study evaluates the safety and efficacy of different DAAs based therapies among mono-
infected CHC elderly patients in clinical follow-up in Spain. The SVR12 per ITT was 88.3%. 
Although the number of elderly patients in our cohort treated with the different new regimens, it 
does not allow us to conclude which are the most tolerated regimens. 
 
This study identifies RBV and PI as the most likely drugs to cause AE. In this cohort, when a 
PI is part of the regimen, AE were three times more frequent, independently of RBV use. No 
patient treated with RBV and DAAs stopped medication due to AE [12]. Three patients who 
discontinued treatment were getting a PI based therapy: 2 cases in combination with Peg-IFN and 
other development a HCC. Therefore, we did not find any association between PI-based therapies 
and discontinuations. 
 
Overall, the SVR12 was high, even for the first generation of PI. Of note, in this population the 
use of Peg-IFN had a negative impact in the SVR12; three of the five patients who failed were on 
Peg-IFN based regimes, nowadays contraindicated for this special population. Prior to advent of 
DAA based regimens, differences in terms of SVR12 between elderly and non-elderly patients 
could have been influenced by low tolerance to Peg-IFN + RBV regimens [13]. At present, there 
are several results from clinical trials using DAAs [14], recognising similar SVR12 in both age 
groups and are very similar rates of SVR observed in this study. 
 
Two patients were diagnosed with HCC during treatment. A recent study shows an increased 
tendency to develop an HCC after HCV treatment initiation, using DAAs in patients who have 
already been cured of a previous occurrence. At this moment, any conclusion should be made and 
we need to be cautious with these results [15]. 
 
There is scarce data about the clinical evolution in elderly patients after HCV cure [16]. 
Several mathematical natural history models predict an increasing tendency in liver 
decompensation and deaths related to HCV over the next 10 years [17] ;  [18]. However, this 
tendency might be modified with the recent introduction of DAAs. 
 
In this context, there is a lack of data in relation to the cost-effectiveness of treatment with 
DAAs in elderly patients [19]. More studies must be conducted to clarify the benefits of these 
therapies in this special population. 
 
There are some limitations in this study that might be considered. There are included IFN and 
no IFN-based regimens, where tolerance, adherence and rates of SVR12 have huge differences. 
The sample size and the short FU period does not allow to conclude differences in prognosis. 
 
In conclusion, elderly patients achieved high rates of SVR12 with DAAs regimens. However, 
AE and modification of chronic medications make these patients a special population, where we 
had to exercise more care. 
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